Key result
Cardiotrophin-1 protected cultured rat cardiocytes from simulated ischaemia/reoxygenation injury when added prior to ischaemia or at reoxygenation, dependent on the p42/p44 MAPK pathway.
Why the study?
Does cardiotrophin-1 protect cultured rat cardiocytes from injury when added prior to simulated ischaemia or at reoxygenation?
Does cardiotrophin-1 protect cultured rat cardiocytes from injury when added prior to simulated ischaemia or at reoxygenation?
Cardiotrophin-1 protects cultured rat cardiocytes from ischemia/reoxygenation injury when administered either before ischemia or at reperfusion via the p42/p44 MAPK pathway.
Answers are grounded in this paper and cite their sources.
Protects cultured cardiocytes from simulated ischemia-reoxygenation in vitro; extends prior cytoprotection findings but leaves clinical translation open.
OBJECTIVE: The cytokine cardiotrophin-1 (CT-1) has previously been shown to protect cultured cardiocytes from cell death induced by serum removal or hypoxia when administered prior to the damaging stimulus. We wished to test whether a similar protective effect could be observed if CT-1 was added after the ischaemic period and to investigate the signalling pathways involved in the protective effect when CT-1 is given prior to or after ischaemia. METHODS: We therefore examined the protective effect of CT-1 in cultured rat cardiocytes exposed to simulated ischaemia followed by reoxygenation when CT-1 was administered either prior to simulated ischaemia or at reoxygenation. RESULTS: We show that CT-1 can exert a protective effect against the damaging effects of simulated ischaemia/reoxygenation both when added after the simulated ischaemia at reoxygenation (P<0.05 in trypan blue, TUNEL and annexin V assays) or when added prior to the simulated ischaemia (P<0.05). In both cases, these protective effects are blocked by an inhibitor of the p42/p44 MAPK pathway (P<0.05 in all assays). CONCLUSION: CT-1 can protect cardiac cells when added either prior to simulated ischaemia or at the time of reoxygenation following simulated ischaemia and these effects are dependent upon its ability to activate the p42/p44 MAPK pathway. Hence CT-1 may have therapeutic potential when added at the time of reperfusion following ischaemic damage.
No takes yet. Share an insight, caveat, or question.
Bhawanjit K. Brar (2001) studied Simulated ischaemia/reoxygenation injury. Cardiotrophin-1 (CT-1) vs. Control (no CT-1) was evaluated on Cell death (assessed by trypan blue, TUNEL and annexin V assays) (p=<0.05). Cardiotrophin-1 protected cultured rat cardiocytes from simulated ischaemia/reoxygenation injury when added prior to ischaemia or at reoxygenation, dependent on the p42/p44 MAPK pathway.
Synapse has enriched 10 related papers. Consider them for comparative context: